Positrigo AG: Market Research Report

Company Overview

• Name: Positrigo AG

• Mission: To make functional imaging accessible for people worldwide and create a lasting social impact. The focus is on advancing clinical routine and enabling research in diagnostics, treatment monitoring, and the development of new therapies.

• Year Founded: 2018

• Founders: Dr. Jannis Fischer, Dr. Max Ahnen

• Key People:

• Dr. Jannis Fischer, Founder & CEO

• Dr. Max Ahnen, Founder & COO

• Dr. Stefan Bircher, CCO

• Dr. Ilaria Sacco, CTO

• Ron Lissak, EVP & GM Positrigo Inc.

• Headquarters: Technoparkstrasse 1, Zeppelin Wing, 5th Floor, Office 5009-5010, 8005 Zurich, Switzerland

• Number of employees: No information is available.

• Revenue: No information is available.

• Known for: Developing nuclear medical imaging devices, specifically an ultra-compact brain Positron Emission Tomography (PET) system known as NeuroLF.

Products

NeuroLF System

• Description: The NeuroLF System is an ultra-compact, dedicated brain Positron Emission Tomography (PET) system that offers functional brain imaging at a fraction of current costs. It is particularly applicable for diagnosing dementia and Alzheimer’s disease, along with various other brain-related disorders.

• Key Features:

• Limited space requirements

• Intuitive and easy to use

• High patient comfort and satisfaction

• Compelling price-value proposition

• Functionality includes seated scans, reducing the need for large space and special room modifications.

Recent Developments

Securing Major Market Approvals

• CE Mark Approval in Europe: On October 2, 2024, Positrigo secured a CE Mark for the NeuroLF System, making it the first dedicated brain PET system approved in both the US and Europe. This approval indicates a significant advancement in brain PET imaging.

• FDA Clearance in the US: As of July 16, 2024, NeuroLF received FDA clearance, allowing it for sale in the US. The device is ultra-compact and patient-friendly, designed to assist with diagnosing various brain disorders while requiring minimal space.

US Market Expansion

• US Subsidiary Launch: In October 2023, Positrigo established its US subsidiary to penetrate the US market following the FDA clearance. The US market shows promising growth, driven by increased demand due to disease-modifying therapies for Alzheimer's and amyloid PET reimbursement improvements by Medicare.

Strategic Collaborations

• Collaboration with Bottneuro: In November 2021, Positrigo signed an agreement with Bottneuro to advance early diagnosis and personalized treatments for Alzheimer's disease, supporting innovative treatment centers with NeuroLF devices.

Funding and Accolades

• Series B Funding Round: On October 24, 2022, Positrigo raised CHF 5.5 million to accelerate commercialization efforts. The total raised to date surpasses CHF 13 million.

• Innosuisse Swiss Accelerator Grant: In May 2023, Positrigo received support from Innosuisse under the Swiss Accelerator program, meant to advance its "World-PET Platform."

• Recognition: Listed among the TOP 100 Swiss Startups in September 2022. Participated in the 2021/2022 IMD Startup Competition.

Performance and Advisory Expansion

• Performance Data Release: On June 8, 2023, preliminary performance data of the NeuroLF indicated non-inferiority to conventional PET/CT devices, positively received by the clinical community.

• Advisory Board Enhancement: Introduction of Prof. Simon Cherry to the advisory board, providing his expertise in nuclear medicine imaging.

No further information is available on other products, revenue specifics, or metrics.